News/ News/ News/ Oncology/ R&D/ Top stories UK startup Ervaxx targets ‘dark matter’ of human genome Phil Taylor cancer vaccine, cell therapy, Ervaxx, immuno-oncology, melanoma, UK 0 Comment After two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share X UK startup Ervaxx targets ‘dark matter’ of human genome https://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
cancer vaccine, cell therapy, Ervaxx, immuno-oncology, melanoma, UK
0 Comment
